Back to Stocks

PACB

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Pacific Biosciences is executing a decisive strategic transformation, shifting away from legacy short-read liabilities to focus on its high-margin HiFi long-read sequencing ecosystem.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative of a strategic pivot, PacBio's financial health remains precarious, with the recent 'profit swing' largely attributable to non-recurring events.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every PACB filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical crossroads, having successfully shed the weight of its short-read ambitions but still struggling to bridge the gap to profitability. The divestiture to Illumina provided a necessary liquidity injection and a cleaner strategic focus, but it also highlighted the lack of value in the legacy short-read portfolio. The transition to a consumable-centric model is showing early signs of success through the growth of Revio-related sales, yet the overall revenue remains flat, indicating that hardware sales are stagnating in a constrained funding environment. Ultimately, the investment thesis for PacBio now hinges on the execution of its 2026 product roadmap. If the SPRQ-Nx launch can successfully lower the barrier to entry for clinical users and drive a surge in consumable utilization, the company may finally achieve the scale necessary to offset its high fixed costs. However, until the company can demonstrate a path to positive cash flow without relying on one-time asset sales, it remains a high-risk play sensitive to both macroeconomic funding cycles and geopolitical stability in the semiconductor supply chain.

Selected Quarter

Core Takeaway

PacBio has transitioned from a diversified sequencing company to a pure-play HiFi long-read provider, utilizing a one-time asset sale to Illumina to fund its pivot toward a high-margin consumable model.

Investor Lens

Investors must weigh the potential of the new product catalysts against the risk of persistent cash burn and a heavily leveraged balance sheet.

Watch Next

The commercial launch of SPRQ-Nx kits in May 2026 and subsequent consumable revenue growth in Q2 and Q3.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.22Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 8

Gross profit swung from a loss to $12.8 million due to lower product costs and a shift toward consumables.

margin expansion
70%
bullishMay 8

Sale of short-read DNA sequencing assets to Illumina for $50 million to focus on HiFi long-read technology.

divestiture
60%
bearishMay 8

Company continues to report a net loss of $8.3 million and significant operating cash burn.

earnings miss
40%
neutralMay 8

Management of $645 million in convertible senior notes with restrictive covenants on additional debt.

debt restructure
50%
bullishMay 8

Gross profit swung from a loss to $12.8 million due to lower product costs and a shift toward consumables.

margin expansion
70%
bullishMay 8

Sale of short-read DNA sequencing assets to Illumina for $50 million to focus on HiFi long-read technology.

divestiture
60%
bearishMay 8

Company continues to report a net loss of $8.3 million and significant operating cash burn.

earnings miss
40%
neutralMay 8

Management of $645 million in convertible senior notes with restrictive covenants on additional debt.

debt restructure
50%
bullishMay 8

Gross profit swung from a loss to $12.8 million due to lower product costs and a shift toward consumables.

margin expansion
70%
bullishMay 8

Sale of short-read DNA sequencing assets to Illumina for $50 million to focus on HiFi long-read technology.

divestiture
60%
bearishMay 8

Company continues to report a net loss of $8.3 million and significant operating cash burn.

earnings miss
40%
neutralMay 8

Management of $645 million in convertible senior notes with restrictive covenants on additional debt.

debt restructure
50%
bullishMay 8

Gross profit swung from a loss to $12.8 million due to lower product costs and a shift toward consumables.

margin expansion
70%
bullishMay 8

Sale of short-read DNA sequencing assets to Illumina for $50 million to focus on HiFi long-read technology.

divestiture
60%
bearishMay 8

Company continues to report a net loss of $8.3 million and significant operating cash burn.

earnings miss
40%
neutralMay 8

Management of $645 million in convertible senior notes with restrictive covenants on additional debt.

debt restructure
50%
bullishMay 8

Gross profit swung from a loss to $12.8 million due to lower product costs and a shift toward consumables.

margin expansion
70%
bullishMay 8

Sale of short-read DNA sequencing assets to Illumina for $50 million to focus on HiFi long-read technology.

divestiture
60%
bearishMay 8

Company continues to report a net loss of $8.3 million and significant operating cash burn.

earnings miss
40%
neutralMay 8

Management of $645 million in convertible senior notes with restrictive covenants on additional debt.

debt restructure
50%
bullishMay 8

Gross profit swung from a loss to $12.8 million due to lower product costs and a shift toward consumables.

margin expansion
70%
bullishMay 8

Sale of short-read DNA sequencing assets to Illumina for $50 million to focus on HiFi long-read technology.

divestiture
60%
bearishMay 8

Company continues to report a net loss of $8.3 million and significant operating cash burn.

earnings miss
40%
neutralMay 8

Management of $645 million in convertible senior notes with restrictive covenants on additional debt.

debt restructure
50%
bullishMay 8

Gross profit swung from a loss to $12.8 million due to lower product costs and a shift toward consumables.

margin expansion
70%
bullishMay 8

Sale of short-read DNA sequencing assets to Illumina for $50 million to focus on HiFi long-read technology.

divestiture
60%
bearishMay 8

Company continues to report a net loss of $8.3 million and significant operating cash burn.

earnings miss
40%
neutralMay 8

Management of $645 million in convertible senior notes with restrictive covenants on additional debt.

debt restructure
50%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical crossroads, having successfully shed the weight of its short-read ambitions but still struggling to bridge the gap to profitability. The divestiture to Illumina provided a necessary liquidity injection and a cleaner strategic focus, but it also highlighted the lack of value in the legacy short-read portfolio. The transition to a consumable-centric model is showing early signs of success through the growth of Revio-related sales, yet the overall revenue remains flat, indicating that hardware sales are stagnating in a constrained funding environment. Ultimately, the investment thesis for PacBio now hinges on the execution of its 2026 product roadmap. If the SPRQ-Nx launch can successfully lower the barrier to entry for clinical users and drive a surge in consumable utilization, the company may finally achieve the scale necessary to offset its high fixed costs. However, until the company can demonstrate a path to positive cash flow without relying on one-time asset sales, it remains a high-risk play sensitive to both macroeconomic funding cycles and geopolitical stability in the semiconductor supply chain.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.